Archives — May 2018 back to current month (7)
A ROTH Capital Partners research report outlined the key drivers of the investment thesis for this firm.
Biotech Announces Encouraging HIV Vaccine Results (05/23/2018)
Ram Selvaraju, an analyst with H.C. Wainwright & Co., explained the recently released data from a study of one of this immunotherapy firm's therapeutics.
Cowen analyst Dr. Joshua Jennings highlighted this medical device firm's Q1/18 developments and financial results.
Francois Brisebois, an analyst with Laidlaw & Co., reviewed this firm's progress since commercially debuting its primary asset.
Analyst Douglas Loe with Echelon Wealth Partners discussed this immunotherapy developer's recent and upcoming news.
The terms of a proposed agreement between this cell therapy company and YOFOTO, a Chinese health and consumer products company, have been revised and will result in a $5.1 million investment.
In the second of a two-part series exploring the disruptive cell therapy space, Maxim Group analyst Jason McCarthy takes a look at small-cap companies targeting big-ticket indications and their potential to drive blockbuster value for both patients and investors.
|"PMN is looking to outlicense PMN310 after the Phase 1 study."|
|"VIVs recent distribution deals illustrate demand for its technology."|
|"DRRX intends to start a NASH trial as soon as H1/19."|